The Rise of Smart Auto-Injectors: Beyond Basic Drug Delivery

Global auto-injectors market is anticipated to grow at a significant CAGR of 15.1% during the forecast period (2024-2031). The main factors driving this expansion include the rising incidence of chronic illness, the rise in demand for self-administration tools, and improvements in drug delivery technology. However, the expensive cost of auto-injectors and worries about device malfunctions might somewhat impede market expansion. Companies are concentrating on innovation and diversifying their product portfolios to satisfy a range of patients’ needs as the market gets more and more competitive. 

Browse the full report description of “Auto-Injectors Market Size, Share & Trends Analysis Report by Type (Disposable Auto-injectors, and Reusable Auto-injectors), by Application (Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, and Others), and by End-User (Home Care Settings, Hospitals & Clinics, and Others) Forecast Period (2024-2031)” at https://www.omrglobal.com/industry-reports/auto-injectors-market

Recent Market Developments

• In April 2024, scPharmaceuticals enrolled the first patient in the key pharmacokinetic study of furosemide, or SCP-111, which is administered via auto-injector.

• In January 2024, FUJIFILM Diosynth Biotechnologies entered a strategic relationship with SHL Medical to increase the offerings of the former company's finished goods auto-injectors.

• In September 2023, Ypsomed, a Switzerland-based company, and Novo Nordisk reached an agreement to supply the former company’s YpsoMate 1 mL auto-injectors for various medications (that are now undergoing clinical trials). 

• In April 2022, Halozyme acquired Antares Pharma, for about $960.0 million, or $5.6 per share to enter the auto-injector realm. The company's new acquisition is brought to use auto-injector technologies to add to Halozyme's drug delivery technology. 

Market Coverage

• The market number available for – 2023-2031

• Base year- 2023

• Forecast period- 2024-2031

• Segment Covered-

o By Type

o By Application 

o By End-user

• Regions Covered-

o North America 

o Europe 

o Asia-Pacific 

o Rest of the World 

• Competitive Landscape - Antares Pharma, Inc., Bayer AG, Becton, Dickinson and Co., Eli Lilly and Co., and Novartis International AG among others.

The key question addressed by the Report

• What is the market growth rate? 
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Auto-Injectors Market Report segment

By Type

• Disposable Auto-injectors
• Reusable Auto-injectors

By Application

• Rheumatoid Arthritis
• Multiple Sclerosis
• Anaphylaxis
• Others (Cardiovascular Diseases, and Anemia)

By End-Users

• Home Care Settings
• Hospitals & Clinics
• Others (Research Laboratories)

Global Auto-Injectors Market reports segmented by region

North America 

• United States

• Canada

Europe 

• UK

• Italy

• Spain

• Germany

• France

• Rest of Europe

Asia-Pacific 

• India

• China

• Japan

• South Korea

• Rest of Asia-Pacific

Rest of the World 

• Middle East & Africa

• Latin America

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/auto-injectors-market